RecruitingPhase 1NCT06745297
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
A Two-part, Randomised, Single-blind, Placebo-controlled, Single and Multiple Rising Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BI 3776528, Administered to Healthy Male Participants
Sponsor
Boehringer Ingelheim
Enrollment
172 participants
Start Date
Jan 23, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The trial aims to study the safety, tolerability, and pharmacokinetics of single and multiple rising doses of BI 3776528.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 50 Years
Inclusion Criteria4
- Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination and clinical laboratory.
- Age of 18 to 50 years (inclusive)
- BMI of 18.5 to 29.9 kg/m² (inclusive), body weight above 60 kg (inclusive)
- Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
Exclusion Criteria3
- Any finding in the medical examination (including blood pressure (BP), pulse rate (PR) or electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator
- Repeated measurement at screening of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
- Any laboratory value outside the (age-adapted) reference range that the investigator considers to be of clinical relevance, in particular, hepatic parameters (alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin), renal parameters (creatinine) exceeding the upper limit of normal (ULN) after repeated measurements or abnormal thyroid stimulating hormone (TSH) values outside of the normal range after repeated measurements.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBI 3776528
BI 3776528
DRUGPlacebo matching BI 3776528
Placebo matching BI 3776528
DRUGshort-acting benzodiazepine
short-acting benzodiazepine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06745297
Related Trials
Evaluation of [11C]ZTP-1 to Image PDE4B
NCT076253451 location
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Predicting Future Errors During Skill Performance
NCT067072071 location
Feasibility and Acceptability of Mindful Self-Compassion Among Transgender and Nonbinary Young Adults
NCT064099751 location
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
NCT070233543 locations